Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary ...

GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.

Columnist Sam Kirton marks four years since his bilateral lung transplant by reflecting on his health, his family, and his ...

Columnist Sam Kirton had to make some adjustments after his IPF diagnosis, but there are still plenty of ways to find joy, he says.

Ofev (nintedanib) is an anti-fibrotic medicine marketed by Boehringer Ingelheim that was approved for the treatment of idiopathic pulmonary fibrosis (IPF) in the U.S. in 2014 and in Europe in 2015.

Sam Kirton started his column in November 2021 and writes from his home at Lake Anna, Virginia, where he lives with his wife Susan. His diagnosis at age 59 with idiopathic pulmonary fibrosis in ...

Pulmonary fibrosis is a disease marked by scarring — or fibrosis — of tissue deep in the lungs, making breathing difficult.

Pulmonary fibrosis (PF) is a respiratory condition characterized by the thickening and scarring (also called fibrosis) of the lungs. Because of thickening lung tissue, it is difficult for oxygen to ...

The U.S. Food and Drug Administration has granted Bristol Myers Squibb’s investigational therapy BMS-986278 breakthrough therapy status.

Read about idiopathic pulmonary fibrosis (IPF) — its risk factors, symptoms, and current ways of treating this interstitial lung disease.

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...